Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 4% in the quarter and for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

4Q Revenues: $20.7 billion (+2%)

4Q Earnings: 4.0 billion (+32%)

FY Revenues: $82.1 billion (+1%)

FY Earnings: $15.1 billion (-1%)

Comments: Pharmaceutical sales were $10.5 billion in the quarter, up 4%. For the year pharmaceutical sales were $42.2 billion, up 4%. Growth for the year was driven by STELARA for the treatment of immune-mediated inflammatory diseases, DARZALEX for the treatment of multiple myeloma, IMBRUVICA for treating certain B-cell malignancies, TREMFYA for the treatment of moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA for the treatment of schizophrenia, and ERLEADA, a next-generation androgen receptor inhibitor for the treatment of prostate cancer. Growth was partially offset by biosimilar and generic competition, primarily declines in REMICADE, U.S. ZYTIGA and international VELCADE.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters